Jan Cools

Editor-in-Chief HemaSphere, Group Leader VIB, Professor KU Leuven

[Jan Cools @CoolsJn]

Finally!! The first 2024 issue of HemaSphere Journal is now available. A lot has changed: Wiley is our new publisher, easier to submit & new website...
All good things remained: #openaccess, expert review, low publication fees, excellent research, high impact, dedicated editors

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

🎉Our first 2024 issue is finally online, with more papers coming next week! https://t.co/4zOVVr99Ro
We're proud to now publish with Wiley, offering easy submission, transformative agreements (many authors will incur zero APCs!), + much more. Lots of good changes, all while we hold close our priorities of excellent science, accessibility, & low fees.

[Jan Cools @CoolsJn]

@DavidSteensma Good point, we should consider to change this at @Hemasphere_EHA ! (Except for @rosslevinemd )

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

In this Review Article published in the June issue of HemaSphere,  new pharmacological treatments have the potential to address unmet needs by direct oral anticoagulants in acute and long-term management and prevention of venous thromboembolism. 👉https://t.co/FyEgXZiUnd

@QThillo @VerhammePeter

[Jan Cools @CoolsJn]

In addition to my passion for #hematology and @Hemasphere_EHA, I also try to play the #piano and make my own songs… Here is what Pieter Savenberg did with one of my motifs - check out his wonderful music at https://t.co/QoTKwaTjjn

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

📣HemaSphere's June issue is now complete!

Read about new horizons in the management of #VenousThromboembolism, a retrospective study on efficacy of treatment in #VEXAS,  a review on #NK-LGLL, and more  Have a browse📰 https://t.co/nzxi7TOhK8

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

At #EHA2025, HemaSphere was honored to award authors of 4 recent + highly influential publications that significantly contribute to the hematology field. Congrats to Giancarlo Castaman et al for their clinical practice guideline on antithrombotic treatment in patients with hemophilia 👉https://t.co/n1SEFIYcRW

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

At #EHA2025, HemaSphere was honored to award authors of 4 recent + highly influential publications that significantly contribute to the hematology field. Congrats to Thomas Beder & coauthors for their publication about ALLCatchR identifying B-cell precursor ALL subtypes 👉https://t.co/6FqTRTZ3Wl

[Jan Cools @CoolsJn]

Exciting to share the new impact factor of @Hemasphere_EHA : 14.6 - ranking as number 5 of 99 hematology journals (Source: Journal Citations Reports, Clarivate). @EHA_Hematology https://t.co/3zUUmb6hYA

[Jan Cools @CoolsJn]

Join us today at #EHA2025 for the @Hemasphere_EHA session

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

🚨Today! @ 15:45, MiCo room CORAL 6 
We warmly invite you to the HemaSphere Scientific Session where we will dive into 3 of our exciting + cutting-edge biology publications. Hope to see you there!
🕰️: 15:45 - 16:45
📍: Room CORAL 6, #EHA2025
🎤: https://t.co/mwHg8y1Y5F

[Jan Cools @CoolsJn]

Thank you @EHA_Hematology, for honoring me with the Education and Mentoring Award. Thank you Peter Marynen and Gary Gilliland for being such inspiring mentors to me. Thank you to all my trainees, all current and past members of my research group. #EHA2025

[Jan Cools @CoolsJn]

Join us on Saturday at #EHA2025 for a scientific session presenting exciting data on 3 recently published articles from @Hemasphere_EHA - journal of @EHA_Hematology

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

Attention fundamental #hematology researchers: we warmly invite you to the HemaSphere Scientific Session at #EHA2025.
Dive into 3 of our exciting + cutting-edge biology publications. Mark your cals & see you there!
📆: Saturday, June 14
🕰️: 15:45 - 16:45
📍: MiCo, Room CORAL 6
🎤: https://t.co/c3Mkj1TXfA

[Jan Cools @CoolsJn]

Join us this Friday at #EHA2025 for an interactive workshop on reviewing for scientific journals!
@Hemasphere_EHA
@EHA_Hematology

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

Interested in training for the role of a scientific journal peer reviewer? Curious how you can fine-tune your manuscript to shine its brightest for reviewers?. Mark your #EHA2025 agenda - HemaSphere has you covered!
🎓Peer Review Workshop
📆Friday, June 13
⏱️13:30 - 15:00
📍Milan MiCo, Room Ocean 2

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

2024 has been a successful year for HemaSphere Journal!
 800+ manuscript submissions
 increasing impact in the field
 insightful graphical abstracts
 another podcast season
 ...and of course, excellent research!

We extend a warm thank you to all authors, reviewers & readers ❤️

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

📖HemaSphere's December issue is now complete 👉https://t.co/4pDU98jVli and as always, is 100% #OpenAccess. Please enjoy reading and feel free to share with your networks.

[Jan Cools @CoolsJn]

@rosslevinemd Agree!!

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

Microbes support normal blood production! Authors in this recently published article report on the microbes and microbial metabolites missing from pediatric patients with antibiotic-associated neutropenia. @TheKingLab 👉https://t.co/Cy8eQa4hjL

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

This population-based study examined COD in 20K+ CLL patients in the Netherlands between 1996 and 2020. Findings reveal CLL as the predominant COD, around 40% of relative mortality, with a declining 5-year death probability from 16.8% in 1996–2002 to 7.6% in 2010–2020. This comprehensive analysis underscores a noticeable reduction in CLL-attributed deaths and other competing causes, yet as CLL is registered as the most prevalent cause of mortality among contemporary diagnosed patients, this emphasizes the continued relevance of CLL-centric clinical strategies and research.

Read about it 👉https://t.co/b54NkK4ln5

[Jan Cools @CoolsJn]

What a great party we had yesterday @vib_ccb 🎉 Thanks to all members of our VIB center for the wonderful evening, and congrats to my team for putting a nice dance act together and winning the second prize 😍

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

Podcast Replay 2024!

Scientific Editor Dr Charles de Bock hosts Dr Thomas Mercher and Dr Alexandre Fagnan in this episode based on their recent paper, “The ETO2 transcriptional co-factor maintains acute leukemia by driving a MYB/EP300-dependent stemness program”, highlighting ETO2 activated gene transcription and how this affects erythroleukemia. The discussion traces the journey from Dr Fagnan’s PhD project (2022 #EHA Junior Grant awardee), the findings in the paper and what may lie beyond

“A transcriptional cofactor‐mediated dependency module”, is on our website and all major podcast platforms (Spotify, Apple Podcast, and more) and our YouTube channel https://t.co/mcdGoXTdNC

Listen and enjoy casual, insightful discussions about #hematology research. 

You can find the referenced article, in full and open access, here on the HemaSphere website https://t.co/hJfDhP0lDa

[HemaSphere Journal (IF = 14.6) @Hemasphere_EHA]

🥳We are honored to have the heme community's support.

[European Hematology Association @EHA_Hematology]

Start your 2025 with the latest in hematology research at #EHAReCon2025 in Málaga, Spain.
With one month left to save on your registration, this is your opportunity to connect with our community of basic scientists, access key scientific and educational sessions, network with colleagues and scientific journal representatives, and more.

Learn more: https://t.co/t6mlZ2ujZc